A single arm phase II study of ADjuvant Endocrine therapy subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive HER2-positive breast cancer (ADEPT)

Brief description of study

You can participate in this study if you are diagnosed with stage I, hormone receptor-positive (HR+) and human epidermal growth factor receptor-2.positive (HER2+) breast cancer. The purpose of this study is to treat breast cancer with endocrine therapy without chemotherapy in patients with stage I (HR+) and HER2-positive breast cancer. After completion of primary breast surgery, patients will be registered to the trial, and receive adjuvant trastuzumab (an antibody which helps the immune system kill cancer cells), pertuzumab (an antibody which helps the immune system kill cancer cells) and hormonal therapy. The study also determines how the body handles study drugs, and how the study drugs are absorbed (taken up in the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medications during the entire study period.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.